NCT05075746 is a clinical trial of enVista Toric in Corneal Astigmatism, sponsored by Bausch & Lomb Incorporated.

Who is sponsoring NCT05075746?

NCT05075746 is sponsored by Bausch & Lomb Incorporated.

What drugs are being tested in NCT05075746?

Interventions in NCT05075746: enVista Toric, enVista non-Toric (spherical).

What condition does NCT05075746 study?

NCT05075746 studies Corneal Astigmatism.

Is NCT05075746 still recruiting?

NCT05075746 is currently completed. Last updated 27 March 2024.

Are results published for NCT05075746?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-03-27 · How we verify

NCT05075746

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retrospective Chart Review of enVista Toric 0.9D Intraocular Lenses

Completed Results posted Last updated 27 March 2024

What this trial tests

trial testing enVista Toric in Corneal Astigmatism in 302 participants. Completed in 3 January 2023.

Timeline

8 March 2022

Primary endpoint
3 January 2023

3 January 2023

Quick facts

Lead sponsor	Bausch & Lomb Incorporated
Status	Completed
Study type	OBSERVATIONAL
Enrollment	302
Start date	8 March 2022
Primary completion	3 January 2023
Estimated completion	3 January 2023
Sites	3 locations across Canada

Drugs / interventions tested

enVista Toric
enVista non-Toric (spherical)

Conditions studied

Corneal Astigmatism — all drugs for Corneal Astigmatism →

Sponsor

Bausch & Lomb Incorporated — full company profile →

Who can join

18 and older, any sex, with Corneal Astigmatism. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Mean Reduction in Cylindrical Power of the Eye Primary · 4 weeks after IOL implantation

Reduction in the cylindrical power of the eye is defined as the difference between the magnitudes of the preoperative keratometric cylinder and the residual refractive cylinder (referenced to the corneal plane).

Group	Value	95% CI
enVista Toric 0.9D Intra Ocular Lens	0.432	± 0.4468
enVista Non-Toric (Spherical) Intra Ocular Lens	0.071	± 0.4073

Adverse events — posted to ClinicalTrials.gov

Time frame: 4 weeks after IOL implantation. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

enVista Toric 0.9D Intra Ocular Lens

Serious: 0/157 (0%)

Deaths: 0/157

enVista Non-Toric (Spherical) Intra Ocular Lens

Serious: 0/145 (0%)

Deaths: 0/145

Other adverse events (1 terms — click to expand)

Reaction	System	enVista Toric 0.9D Intra O…	enVista Non-Toric (Spheric…
Posterior Capsule Opafication	Eye disorders	—	—

Data from ClinicalTrials.gov NCT05075746 adverse events section.

Sponsor's own description

The primary objective of this study is to evaluate the performance of the enVista Toric 0.9D vs non-Toric IOL.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of Astigmatic Outcomes with an Ultra-Low Cylinder Power (0.90 D) Toric versus a Non-Toric Intraocular Lens for Eyes with Low Astigmatism.
Muzychuk A, Kranemann CF. · · 2026 · PMID 41868569 · DOI 10.2147/opth.s563478

Verify or expand the search:

Other recruiting trials for Corneal Astigmatism

Currently open trials in the same condition.

NCT07081919 — Effectiveness, Stability and Influence Factors of Femtosecond Laser Assisted Cataract Surgery · recruiting
NCT03841253 — Treatment of Vision Disturbances Due to Corneal Irregularities by Trans-epithelial Optical Phototherapeutic Keratectomy · NA · active not recruiting
NCT04251143 — Dresden Corneal Disease and Treatment Study · recruiting

Other Bausch & Lomb Incorporated trials

Trials by the same sponsor.

NCT07054606 — A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear · Phase 4 · completed
NCT06803654 — A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Rel · Phase 3 · completed
NCT06594185 — A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects · NA · completed
NCT06479148 — Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens · NA · terminated
NCT06333028 — A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05075746 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bausch & Lomb Incorporated
Last refreshed: 27 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05075746.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing